BioCryst Pharmaceuticals, Inc.
BCRX
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930ā¦ read more
Healthcare
Biotechnology
32 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$8.98
Price-2.81%
-$0.26
1Y
Price
Market Cap
$2.282b
Mid
Price/Earnings 3y Avg5y Avg
6.9x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+20.2%
EBITDA Margin+8.1%
Net Profit Margin+25.0%
Free Cash Flow Margin+20.2%
EBITDA Margin+8.1%
Net Profit Margin+25.0%
Free Cash Flow MarginRevenue
$885.716m
+33.1%
1y CAGR+30.5%
3y CAGR+40.9%
5y CAGREarnings
-$457.983m
+90.1%
1y CAGR+53.1%
3y CAGR+31.2%
5y CAGREPS
-$1.78
+88.4%
1y CAGR+54.4%
3y CAGR+33.5%
5y CAGRBook Value
-$553.843m
$465.052m
Assets$1.019b
Liabilities$858.083m
DebtDebt to Assets
184.5%
8.1x
Debt to EBITDAFree Cash Flow
$294.098m
+189.1%
1y CAGR+91.6%
3y CAGR+65.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company